Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

PETNET Solutions providing essential PET diagnostic radiopharmaceuticals for effective theranostics.

Diagnostic Radiopharmaceuticals 
for Theranostics
PETNET Solutions provides essential PET diagnostic radiopharmaceuticals for effective theranostics

Theranostics begins with diagnostics

PETNET Solutions can help you maintain PET/CT imaging continuity with a vast distribution network providing the efficient delivery of PET radiopharmaceuticals necessary for the diagnostic phase of theranostics. 

Patient Selection

Theranostics targets disease states through molecular imaging techniques and the use of radioisotopes to deliver personalized medicine. PETNET Solutions offers the most extensive network of radiopharmacies and a comprehensive portfolio to support the diagnostic needs of your imaging center. 

Early and accurate detection may lead to earlier intervention, improving outcomes and potentially reducing the severity of the disease. Determining the extent of the disease assists clinicians in choosing appropriate patients for treatment and ensure optimal outcomes for patients.

 

Patient selection Pre-therapy PET 18F-PSMA

Patient selection
Pre-therapy PET 18F-PSMA

Appropriate patient selection is key to optimizing patient outcomes. For example, the use of PSMA-targeted therapy will only be effective against tumor lesions with sufficient expression of the target receptor.

Emerging data has shown the superiority of PSMA imaging with PET/CT over conventional imaging for primary diagnoses. Single photon emission computed tomography (SPECT) is more available worldwide, and the imaging agent is low in cost.The pattern of tumor PSMA expression should be evaluated per molecular imaging (preferred: 68Ga/18F-PSMA PET; alternatively: 99mTc-PSMA SPECT)2

In this case, a comprehensive evaluation of initial metastatic burden a pre-therapy 18F-PSMA PET scan displayed significant burden of PSMA-avid abdominopelvic and mediastinal nodal metastases.  


Data courtesy of University Hospital Heidelberg, Heidelberg, Germany.

Once the extent of disease has been confirmed 177Lu-PSMA therapy was given with post therapy planar imaging following each cycle.

177Lu-PSMA therapy


Once the extent of disease has been confirmed 177Lu-PSMA therapy was given with post therapy planar imaging following each cycle. 

18F-PSMA PET performed 1 year following therapy shows complete response to therapy with absence of PSMA-avid disease

Post-therapy imaging


18F-PSMA PET performed 1 year following therapy shows complete response to therapy with absence of PSMA-avid disease

Education opportunity

Lady Sawoszczyk, BS, CNMT is the Global Lead for Theranostics Solutions at Siemens Healthineers, where she offers consulting services to healthcare institutions on establishing and optimizing theranostics programs.

Theranostics is rapidly growing due to its ability to offer personalized medicine, enabling more precise targeting of treatments based on a patient's specific disease. Advances in imaging technologies have fueled this growth, improving the accuracy of diagnoses and effectiveness of treatments.

Join Lady Sawoszczyk, BS, CNMT, Global Lead for Theranostics Solutions at Siemens Healthineers, for an insightful session on establishing and optimizing a theranostic program. Drawing from her extensive experience, Lady provides consulting services to healthcare institutions, guiding them through the development and enhancement of their theranostics programs. Previously, at a large academic medical center in New York City, she developed a comprehensive theranostics program encompassing imaging, clinical trials, radiopharmaceutical manufacturing, and patient management software. 

Current PETNET Solutions customers can access 23 on-demand educational webinars with free VOICE CEC on MI PET Source.

Discover resources from PETNET to help support your theranostics program

Explore our offerings along the cancer care continuum

Using molecular imaging to identify specific biomarkers, theranostics allows targeted treatment tailored to individual patients, improving efficacy and minimizing side effects. This integrated approach enhances precision in diagnosing diseases like cancer and delivering therapies directly to affected tissues, revolutionizing patient care. 
Discover how theranostics is transforming personalized medicine.

Contact us


PETNET Solutions customer care team 
email: customercare@petnetsolutions.com 
phone: (877)-473-8643

PETNET Solutions Corporate Office
810 Innovation Drive
Knoxville, TN 37932 USA